Fresolimumab

Fresolimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTGF beta 1, 2 and 3
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6392H9926N1698O2026S44
Molar mass144388.22 g·mol−1
 NY (what is this?)  (verify)

Fresolimumab (GC1008) is a human monoclonal antibody[1] and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer[2][3] (kidney cancer and melanoma).

It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β).[2]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 23 (2). 2009.
  2. ^ a b "Fresolimumab". NCI Drug Dictionary. National Cancer Institute.
  3. ^ "Fresolimumab" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.